Filing summary
Entity mismatch: The supplied filing is Zafgen, Inc.’s Form 10-Q, not a filing by Larimar Therapeutics, Inc. Verify the issuer before relying on this summary.
Business context and reporting period
This unaudited quarterly report covers the three and nine months ended September 30, 2017; it was signed November 7, 2017. Zafgen was a clinical-stage biopharmaceutical company focused on MetAP2 inhibitors. Its lead candidate, ZGN-1061, was being developed for type 2 diabetes and related metabolic disorders. The company had no product revenue.
Financial results and position
Amounts below are in U.S. dollars; financial statement figures were reported in thousands.
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $9.7m | $10.0m | $29.9m | $32.7m |
| General and administrative expense | $3.1m | $4.8m | $9.7m | $15.1m |
| Net loss | $12.6m | $14.7m | $38.9m | $47.4m |
| Net loss per share, diluted | $0.46 | $0.54 | $1.42 | $1.74 |
- No meaningful revenue or profit margins were reported, as the company had no revenue and operated at a loss.
- At September 30, 2017, cash and cash equivalents were $19.2m and marketable securities were $74.0m, totaling $93.2m in cash, cash equivalents and marketable securities. Total current assets were $95.7m; total liabilities were $7.0m, including $1.3m of current notes payable. Stockholders’ equity was $89.2m.
- For the first nine months, operating cash use was $33.9m, investing activities provided $23.0m (principally net sales and maturities of securities), and financing activities used $2.2m. Cash and cash equivalents declined $13.2m.
- Outstanding credit-facility debt was secured by substantially all personal property other than intellectual property; the filing reports an effective annual interest rate of approximately 10.8%. The facility included restrictive covenants but no financial covenants.
Changes versus the prior comparable period
- Nine-month net loss narrowed by $8.5m, while total operating expenses fell $8.1m. Lower beloranib costs following suspension of that program in July 2016 and lower G&A after a workforce reduction drove much of the decrease.
- Nine-month R&D expense declined $2.7m overall, despite a $9.6m increase in ZGN-1061 spending and a $3.7m increase in discovery and screening; reduced beloranib spending more than offset those increases.
- Q3 R&D expense was down $0.3m year over year: lower beloranib spending was largely offset by higher ZGN-1061 and discovery spending.
- Cash, cash equivalents and marketable securities declined from $129.2m at December 31, 2016 to $93.2m at September 30, 2017.
Outlook, commentary and risks
- Management expected available cash, cash equivalents and marketable securities to fund anticipated operations and capital expenditures for at least one year from the report’s issuance. The company cautioned that estimates depended on assumptions and funds could be used sooner than expected.
- ZGN-1061 had completed Phase 1, with management reporting favorable tolerability and no identified prothrombotic safety signal in that trial. A Phase 2 trial had begun in Australia and New Zealand, targeting approximately 120 patients and 12 weeks of dosing. These early findings do not establish later-stage safety or efficacy.
- Management expected substantial continuing losses and development spending. Additional financing would be needed for ongoing development and eventual commercialization; financing might be unavailable or require dilution, debt restrictions, or relinquishment of product rights.
- Key risks include dependence on a single clinical-stage candidate, potential safety issues—including thrombotic risks observed with the earlier candidate beloranib—clinical and regulatory setbacks, trial enrollment and manufacturing delays, reliance on third parties, and the need for additional capital.
- Beloranib licensing agreements could require up to $12.3m in pre-commercialization milestones and up to $12.5m in commercialization milestones, plus royalties if products are commercialized. No milestones were achieved in the reported periods.
- A securities class action concerning beloranib disclosures was dismissed with prejudice; the dismissal was affirmed on appeal on April 7, 2017. Management reported no other material claims known as of September 30, 2017.
- In October 2017, the company granted inducement options to its newly appointed CEO: 550,000 shares under standard vesting and 1.1m shares tied to stock-price appreciation and other performance goals. Additional performance-based options for 275,000 shares were granted to the President and Chief Scientific Officer.
Important facts for investors to verify
- Confirm issuer identity: this filing names Zafgen, Inc., whereas the request identifies Larimar Therapeutics, Inc.
- Check subsequent Phase 2 enrollment, results, safety findings and regulatory developments for ZGN-1061.
- Assess cash burn, investment balances and financing needs against the stated minimum one-year runway, including whether later disclosures revised the forecast.
- Review the credit facility’s repayment status, collateral and covenants, and the contingent beloranib license payments and royalty obligations.
- Evaluate the effect of the October 2017 inducement awards and any later equity issuance on share count and dilution.